Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ...

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm. GSK and ...

Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...

Cellectis has announced that its board of directors have approved a strategic transformation to become an in vivo gene ...

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing ...

Specifically, patients with high cortisol levels face unique challenges that GLP-1s may not be able to tackle. Dr. Elena Christofides: We have been doing a significant amount of medical education — ...

Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in ...

Consolidation to a day-to-day “Novo” name seeks consistent global recognition while retaining Novo Nordisk A/S as the legal ...

Carl Valenstein is a partner with Morgan Lewis and co-leads the firm’s Environmental, Social, and Governance (ESG) & Sustainability team. Shabeena Sharak, a summer associate with the firm, contributed ...

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...